May 2nd 2024
In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Expert Says Lenvatinib Is Standard Frontline Option for RAI-Refractory DTC
April 6th 2016The multikinase inhibitor lenvatinib (Lenvima) has quickly become the frontline standard of care for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), just one year following its initial approval, according to Renato Martins, MD.
Read More
Dr. Maria E. Cabanillas on Reducing Time to Treatment for Anaplastic Thyroid Cancer
March 10th 2016Cabanillas says her and her team set a goal of reducing the time between when they are contacted about a patient with anaplastic thyroid cancer, and when the patient is given an appointment time, to fewer than 5 business days.
Watch
Oncogenic TSHR Mutation in Papillary Thyroid Cancer
March 4th 2016We present a case of a 49-year-old woman with a pT4aN1B papillary thyroid cancer who underwent radical thyroidectomy with bilateral neck dissection and RAI I-131 ablation, but poorly tolerated TSH suppression therapy due to tachycardia. Rising thyroglobulin levels and lymph node mapping showed recurrent/progressive disease in the thyroid bed.
Read More
Patient-Derived Xenografts Could Personalize Anaplastic Thyroid Cancer Care
February 17th 2016Anaplastic thyroid cancer is an extremely aggressive form of cancer that cannot be cured by surgery and has a median survival of about 6 months. The malignancy normally occurs in patients over the age of 60, and there is not a standard of care, according to John A. Copland III, PhD, professor, Cancer Biology, Mayo Clinic.
Read More
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer
February 16th 2016Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Watch
Advanced Thyroid Cancer Responds Well to Targeted Therapies
November 6th 2015The kinase inhibitors sorafenib (Nexavar) and lenvatinib (Lenvima) have significantly altered the treatment paradigm for patients with advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer in both older and younger populations, with combination strategies hoping to further build upon this success.
Read More
Dr. Paul Walfish on PD-1 Expression in Thyroid Cancer
October 24th 2015Paul Walfish, MD, professor emeritus at the University of Toronto School of Medicine, senior consult Mount Sinai Hospital discusses programmed death ligand 1 (PD-1) expression in aggressive metastatic papillary thyroid cancer.
Read More
Dr. Michael Tuttle on Dosimetry Versus Empiric Dosing Radioactive Iodine Treatment
October 23rd 2015Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.
Read More
Dr. Sylvia Asa on Thyroid Cancer Genotyping
October 20th 2015Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Watch